Product Description
Anastrozole is used to treat early hormone receptor-positive breast cancer. It is also used for first-line treatment of hormone receptor-positive or hormone receptor-unknown advanced or metastatic (cancer that has spread) breast cancer. Anastrozole is also used to treat advanced breast cancer that has grown or spread after tamoxifen treatment. (Sourced from: https://www.mayoclinic.org/drugs-supplements/anastrozole-oral-route/description/drg-20061868)
Mechanisms of Action: ARO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Breast Cancer | Oncology Solid Tumor Unspecified | Oncology Unspecified
Known Adverse Events: Hypertension | Depressive Disorder | Back Pain | Headache | Pain Unspecified | Insomnia | Pharyngitis | Breast Cancer Lymphedema | Lymphedema | Osteoporosis | Arthralgia | Arthritis | Osteoarthritis | Bone Cancer | Breast Cancer | Oncology Unspecified | Dyspnea | Asthenia | Edema | Hot Flashes
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Georgia, Germany, Japan, Spain, United States, Unknown Location
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Breast Cancer
Phase 2: Clear Cell Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma|Male Breast Cancer|Serous Cystadenocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ADEPT | P2 |
Recruiting |
Breast Cancer |
2026-09-01 |
|
| IRB00081369 | P2 |
Active, not recruiting |
Male Breast Cancer |
2026-06-30 |
|
| 20P.829 | P2 |
Active, not recruiting |
Endometrioid Carcinoma|Serous Cystadenocarcinoma|Endometrial Cancer|Clear Cell Adenocarcinoma |
2024-12-31 |
|
| XZP-3287-3002 | P3 |
Not yet recruiting |
Breast Cancer |
2024-12-01 |
40% |
| XZP-3287-3002 | P3 |
Not yet recruiting |
Breast Cancer |
2024-12-01 |
40% |